Pfizer's Next Multibillion-Dollar COVID Vaccine Move

Pfizer (NYSE:PFE) made one of the smartest decisions in the company's long history earlier this year. It chose to partner with German biotech BioNTech (NASDAQ:BNTX) on the development and commercialization of its COVID-19 vaccine. And the rest, as they say, is history.

The companies' BNT162b2 COVID-19 vaccine became the first to win U.S., U.K., and Canadian emergency use authorizations (EUA). They lined up deals to supply hundreds of millions of doses through 2021.

Pretty much everything has gone right so far, but that might not always be the case. Billions of dollars could hinge on Pfizer's next major COVID vaccine move.